Publications

Detailed Information

SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

DC Field Value Language
dc.contributor.authorLordick, F.-
dc.contributor.authorShitara, K.-
dc.contributor.authorAl-Batran, S. -E-
dc.contributor.authorBang, Y. -J-
dc.contributor.authorCatenacci, D.-
dc.contributor.authorEnzinger, P.-
dc.contributor.authorIlson, D.-
dc.contributor.authorKim, S.-
dc.contributor.authorShah, M. A.-
dc.contributor.authorVan Cutsem, E.-
dc.contributor.authorXu, R. -H-
dc.contributor.authorArozullah, A.-
dc.contributor.authorPark, J. W.-
dc.contributor.authorAjani, J.-
dc.date.accessioned2024-03-08T00:43:00Z-
dc.date.available2024-03-08T00:43:00Z-
dc.date.created2024-03-07-
dc.date.created2024-03-07-
dc.date.created2024-03-07-
dc.date.issued2021-09-
dc.identifier.citationOncology Research and Treatment, Vol.44, pp.218-218-
dc.identifier.issn2296-5270-
dc.identifier.urihttps://hdl.handle.net/10371/199084-
dc.language영어-
dc.publisherS. Karger AG-
dc.titleSPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-
dc.typeArticle-
dc.citation.journaltitleOncology Research and Treatment-
dc.identifier.wosid000760622600398-
dc.citation.endpage218-
dc.citation.startpage218-
dc.citation.volume44-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorBang, Y. -J-
dc.type.docTypeMeeting Abstract-
dc.description.journalClass1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share